RE: CEO doesn't understand contracts that he signs25 Nov 2021 10:27
@Dibs61: These are a selection of questions i have already posted for tonights presentation, i suspect all we will get is mumble, mumble, mumble though...
Question 1:
With what has gone on with the Company over the last 18 months, missed deadlines, disastrous business decisions, unmet deliverables and a period of shambolic operations, Does Colin King think he deserves the continued backing of the Omega shareholders, does he feel his track record warrants remaining in the role of CEO, or has he considered stepping down for the good of the company that has become the laughing stock of the AIM market.
Question 2:
With a reported capacity to produce 2M tests per week since April, and only recent confirmed orders for approx 200K tests to DAM, What exactly have the 200+ reported staff been doing for the last 6 months
Question 3:
Omega's reputation in the market has been eroded by the company's poor results and investor communications, how can the company attract Institutional investors when the market sentiment and the sentiment of the current private investor base is so low.
Question 4:
What are the company doing to address the history of poor market communications that have taken place over the last 18 months. With every market announcement made by the company investors have to now decide what the company has not said rather than looking at what they have. The latest example being the DAM announcement being made on the day the company's test loses its regulator approval to supply to a large proportion of the DAM business.
Question 5:
What logical reason can the company have for signing an exclusivity agreement with DAM for the professional use test that has no minimum order quantities, when historical figures for DAM seems to indicate they are in a position to utilise only a very small fraction of the Omega manufacturing capacity
Question 6:
As stated many times by the company. and in-particular in last year's placing document the Covid pandemic should have been a massive opportunity for a diagnostics company, in reality poor decisions and continual failures have meant that the company has failed to take advantage of any of these opportunities. How can the BoD hold their heads up in the presence of the shareholders here today.
Question 7:
If the company fails to commercialise any of the covid opportunities will they need further help from its investors in the next calender year, if so looking at the recent placing results from another diagnostics company that boasted much and delivered little with regards to Covid revenue, Gendrive, does the company expect a similar 40% discount to be necessary in order to attract investors, noting that even with the discount at that level the company failed to attract the full investment they needed.